Simris Group AB
Develops novel payloads for Antibody-Drug Conjugates from cyanobacteria for cancer.
SIMRIS | ST
Overview
Corporate Details
- ISIN(s):
- SE0008091656 (+1 more)
- LEI:
- 529900P0ACIS2UI3ZX27
- Country:
- Sweden
- Address:
- Herrestadsvägen 24A, 276 50 HAMMENHÖG
- Website:
- https://simris.com/
Description
Simris Group AB is a biotechnology company focused on developing next-generation payloads for Antibody-Drug Conjugates (ADCs) to advance cancer treatment. The company leverages a proprietary technology platform built upon an extensive library of cyanobacterial strains and expertise in natural products. Through its discovery and bioconjugation technologies, Simris develops novel, IP-protected payloads designed to enhance the efficacy and safety profile of ADC therapeutics. The core activity involves identifying unique natural compounds and developing them into products for the pharmaceutical industry.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Simris Group AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Simris Group AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Simris Group AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
